Chief Financial Officer

Nuvalent price target raised by $16 at Piper Sandler, here's why

Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial

Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025

Nuvalent resumed with a Buy at Stifel

Director, Field Health Economics & Outcomes Research (HEOR) / Payer Focused

Nuvalent is an early-stage company focused on creating selective medicines for cancer patients. The Director, Field HEOR will lead medical scientific communications with payer formulary decision makers and develop relationships to optimize patient access to Nuvalent products.

Sign up with Google

Sign in with Google